Assertio Holdings Completes Merger With Zydus Lifesciences
Assertio Holdings finalized its merger with Zydus Lifesciences, triggering key provisions for holders of its 2027 convertible senior notes.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced Monday the successful completion of its merger with India-based Zydus Lifesciences Ltd., a deal that was first formalized under a merger agreement signed May 13, 2026. The transaction, carried out through Zydus Worldwide DMCC — a limited liability company incorporated under the laws of the United Arab Emirates — marks a significant ownership transition for the Lake Forest, Illinois-based pharmaceutical company.
The closing of the merger immediately set off regulatory and contractual obligations tied to Assertio's outstanding 6.50% Convertible Senior Notes due 2027. Under the terms governing those notes, the merger constitutes both a Fundamental Change and a Make-Whole Fundamental Change — two distinct triggering events that grant noteholders specific rights, including the ability to require the company to repurchase their notes or to convert them at adjusted terms designed to compensate for the change in control.
Read more Intel Launches Production of 18A-P, Its Most Advanced Chip Node →
The Make-Whole Fundamental Change provision is particularly notable because it allows eligible noteholders to receive additional shares or equivalent consideration when converting, softening the financial impact of a takeover on debt investors. These protections are standard in convertible note indentures but become highly consequential when a public company is absorbed by a private or foreign acquirer, as is the case here with Zydus Lifesciences, a major global generics manufacturer headquartered in India.
The transaction represents a meaningful expansion of Zydus Lifesciences' footprint in the United States specialty pharmaceutical market. Assertio, which markets branded prescription drugs, becomes a direct asset under the Zydus corporate umbrella following the deal's close. Analysts tracking the generics and specialty pharma space have noted that Indian drugmakers have increasingly pursued U.S. acquisitions to secure branded revenue streams alongside their core generics businesses.
Continue reading at BusinessWire.
